Viking Therapeutics Showcases VK2735 Data at ObesityWeek 2025

Viking Therapeutics, Inc. has announced plans to present new clinical data from its VK2735 obesity program at ObesityWeek 2025, taking place from November 4 to 7 in Atlanta, Georgia. The presentations will focus on the impact of VK2735 on prediabetes and cardiometabolic health, underscoring the company’s commitment to advancing treatments for metabolic disorders.

VK2735 is a dual agonist targeting the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This innovative drug is currently being evaluated in both subcutaneous and oral formulations, with ongoing clinical trials aimed at assessing its potential in treating various metabolic conditions.

Key Presentations at ObesityWeek 2025

One of the major highlights at ObesityWeek will be a poster presentation detailing results from the Phase 2 VENTURE clinical trial. This study explored the effects of VK2735 through 13 weeks of treatment with a subcutaneous formulation in obese patients. The results focus on the drug’s influence on the prevalence of prediabetes and metabolic syndrome, which are critical factors in managing obesity-related health risks.

Additionally, a second presentation will introduce the ongoing Phase 3 VANQUISH-1 study. This trial evaluates the safety and efficacy of subcutaneous VK2735 in adults with obesity or those who are overweight and have at least one weight-related co-morbidity.

Upcoming American Heart Association Sessions

Beyond ObesityWeek, Viking Therapeutics will also participate in the American Heart Association (AHA) Scientific Sessions 2025, scheduled for November 7 to 10 in New Orleans, Louisiana. The company will present two posters during this event. One will detail the ongoing Phase 3 VANQUISH-2 study, which investigates the effects of subcutaneous VK2735 in patients with Type 2 diabetes who are also classified as obese or overweight.

The second poster will analyze the prevalence of cardiometabolic conditions across different body mass index (BMI) categories, highlighting the distinct challenges posed by severe obesity.

Details of the ObesityWeek and AHA presentations include:

– **ObesityWeek 2025**
– **Title:** VANQUISH-1 Study Design: Phase 3 Trial of Subcutaneous VK2735 in Adults with Overweight or Obesity
– **Presenting Author:** Dr. Karen Modesto, Vice President, Clinical Development, Viking Therapeutics
– **Date/Time:** Wednesday, November 5, 2025, 14:30 – 15:30 Eastern Time

– **Title:** Impact of Subcutaneous VK2735 on Weight, Prediabetes, and Cardiometabolic Status: The VENTURE Study
– **Presenting Author:** Dr. Harold Bays, Louisville Metabolic and Atherosclerosis Research Center
– **Date/Time:** Thursday, November 6, 2025, 14:30 – 15:30 Eastern Time

– **AHA Scientific Sessions 2025**
– **Title:** VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Weekly Subcutaneous Administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes
– **Presenting Author:** Dr. Karen Modesto
– **Date/Time:** Saturday, November 8, 2025, 10:30 – 11:30 Central Time

– **Title:** Prevalence of Cardiometabolic Conditions Across Body Mass Index Categories: The Distinct Burden of Severe (Class III) Obesity
– **Presenting Author:** Dr. Saif Rathore, Sandbar Life Sciences
– **Date/Time:** Saturday, November 8, 2025, 14:30 – 15:30 Central Time

Understanding GLP-1 and GIP Agonists

The GLP-1 receptor plays a vital role in regulating glucose levels, appetite, and weight. Activation of this receptor can lead to improved insulin sensitivity, particularly in patients with Type 2 diabetes and obesity. Notable examples of GLP-1 receptor agonists include semaglutide, marketed as Ozempic, Rybelsus, and Wegovy, which have received approval from the U.S. Food and Drug Administration.

Recent studies have explored the potential benefits of co-activating the GIP receptor alongside GLP-1 receptor activation. Tirzepatide, another dual agonist, has also gained FDA approval, demonstrating the growing interest in these innovative therapeutic approaches.

About Viking Therapeutics

Viking Therapeutics is dedicated to developing first-in-class therapies for metabolic and endocrine disorders. The company currently has three compounds in clinical trials, with VK2735 at the forefront. This dual agonist has shown promising safety and efficacy results in Phase 1 and Phase 2 trials.

In addition to VK2735, Viking is advancing VK2809, a selective thyroid hormone receptor beta agonist aimed at treating lipid and metabolic disorders, and VK0214, which targets rare diseases like X-linked adrenoleukodystrophy.

For more information about Viking Therapeutics and its ongoing research, please visit their official website at www.vikingtherapeutics.com.